Baxter Introduces New Tisseel Prima Syringe at 2018 American Association of Gynecologic Laparoscopists Meeting

  • Next-generation syringe provides physicians with enhanced speed,
    precision and control during surgery
  • Reinforces Baxter’s efforts to offer innovative products to
    surgeons in the gynecologic specialty that advance patient care and
    support healing

LAS VEGAS–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a global leader in advancing
surgical innovation, today unveiled the latest design enhancements for
its fibrin sealant product, the Tisseel Prima syringe, at the
2018 American Association of Gynecologic Laparoscopists (AAGL) meeting.
Attendees can visit Baxter’s booth #807 at the AAGL meeting this week
for product demonstrations of the new Prima syringe and the Tisseel
40cm Duplotip Rigid Applicator
, along with the rest of Baxter’s
portfolio of hemostats and sealants that can be used during
gynecological surgeries.

“Launching the Prima syringe illustrates our commitment to
continuously advance our proven product portfolio to better meet
surgeons’ needs,” said Wil Boren, president of Baxter’s Advanced Surgery
business. “We are focused on developing hemostats and sealants that help
gynecologists overcome their biggest challenges to promote healing for
their patients.”

Baxter’s trusted Tisseel fibrin sealant now features the new Prima
syringe, which is a next-generation ergonomic syringe that comes fully
assembled and is eight times easier to push1 than the
previous Tisseel syringe. This allows surgeons to have a higher
level of precision and control during surgery and has a nearly 17
percent quicker thawing time.2 Baxter also unveiled its new Tisseel
40cm Duplotip Rigid Applicator
, an extended length applicator that
is helpful when surgeons need to apply Tisseel to hard to reach
areas laparoscopically. Tisseel is the only major brand of fibrin
sealant to offer a complete portfolio of drip and spray applicators,
allowing surgeons to select the right tools to address individual
patient needs.3,4 Gynecologists often perform procedures
laparoscopically, such as hysterectomies and myomectomies, which
eliminates the need for large abdominal incisions and speeds up the
recovery time.

“I’ve experienced the benefits of Tisseel firsthand with my
patients and it has become a product that I rely on to help stop
bleeding during gynecologic surgeries,” said Kate O’Hanlan, M.D.,
medical director at the Laparoscopic Institute for Gynecology and
Oncology (LIGO) in Portola Valley, California. “When one of my patients
suffers a bleed, I want to be able to stop it as quickly as possible.
I’m excited that the new Tisseel Prima product will allow me to
treat the bleeding more quickly and easily.”

With more than 2,000 publications, including but not limited to clinical
studies, case series and reports across specialties—including
gynecology—data has shown that Tisseel has been an effective
product worldwide for the last 40 years.

About Baxter’s Surgery Portfolio

Baxter is committed to partnering with clinicians to make a meaningful
impact on patient care in operating rooms (OR) in nearly 60 countries.
Surgeons rely on our hemostats to stop bleeding during surgery, our
sealants to close wounds, and our repair patches and biologics to
promote healing. We are focused on pioneering innovative and dependable
surgical tools and programs that help to improve clinical outcomes while
reducing the total cost of care.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading
portfolio of critical care, nutrition, renal, hospital and surgical
products. For more than 85 years, we’ve been operating at the critical
intersection where innovations that save and sustain lives meet the
healthcare providers that make it happen. With products, technologies
and therapies available in more than 100 countries, Baxter’s employees
worldwide are now building upon the company’s rich heritage of medical
breakthroughs to advance the next generation of transformative
healthcare innovations. To learn more, visit www.baxter.com and
follow us on TwitterLinkedIn and Facebook.

Important Safety Information

Tisseel [Fibrin Sealant] Indications

Hemostasis: Tisseel is a fibrin sealant indicated for use as an
adjunct to hemostasis in adult and pediatric patients (>1 month of age)
undergoing surgery when control of bleeding by conventional surgical
techniques (such as suture, ligature, and cautery) is ineffective or
impractical. Tisseel is effective in heparinized patients.

Sealing: Tisseel is a fibrin sealant indicated as an adjunct to
standard surgical techniques (such as suture and ligature) to prevent
leakage from colonic anastomoses following the reversal of temporary
colostomies.

Selected Important Risk Information for Tisseel

For Topical Use Only. Do not inject Tisseel directly into the
circulatory system or into highly vascularized tissue. Intravascular
application of Tisseel can lead to intravascular coagulation, can
result in life-threatening thromboembolic events, and can increase the
likelihood and severity of acute hypersensitivity reactions in
susceptible patients.
Do not use Tisseel in individuals with
a known hypersensitivity to aprotinin.
Apply Tisseel as a
thin layer by dripping or spraying using cannula or spray set.
Do
not use Tisseel for the treatment of severe or brisk arterial or
venous bleeding.
Hypersensitivity or allergic/anaphylactoid
reactions can occur with the use of Tisseel.

This release includes forward-looking statements concerning Tisseel
(including the Tisseel Prima syringe and rigid applicator),
including potential benefits associated with its use. The statements are
based on assumptions about many important factors, including the
following, which could cause actual results to differ materially from
those in the forward-looking statements: satisfaction of regulatory and
other requirements; actions of regulatory bodies and other governmental
authorities; product quality, manufacturing or supply, or patient safety
issues; changes in law and regulations; and other risks identified in
Baxter’s most recent filing on Form 10-K and other SEC filings, all of
which are available on Baxter’s website. Baxter does not undertake to
update its forward-looking statements.

Baxter and Tisseel are registered trademarks of Baxter
International Inc.

1 Baxter Data on File
2 TISSEEL [SUMMARY of
Product Characteristics]. Vienna, Austria: Baxter International Inc. 2016
3
Ethicon Product Catalog. ©2018 Ethicon US, LLC. 03513-080509.
4
Baxter’s Advanced Surgery Product Catalog

Contacts

Baxter International Inc.
Media Contact
Jessica
Szramiak, 224-948-5353
media@baxter.com
or
Investor
Contact

Clare Trachtman, 224-948-3085

Leave a Reply

Sky Optics Media drone video